Imatinib and pegylated IFN-alpha 2b discontinuation in first-line chronic myeloid leukemia patients following a major molecular response

Perttu Koskenvesa, Anna Kreutzman, Peter Rohon, Markus Pihlman, Emmi Vakkila, Anu Rasanen, Mirja Vapaatalo, Kari Remes, Tuija Lundan, Henrik Hjorth-Hansen, Jukka Vakkila, Bengt Simonsson, Satu Mustjoki, Kimmo Porkka

Research output: Contribution to journalArticleScientificpeer-review

Original languageEnglish
JournalEuropean Journal of Haematology
Volume92
Issue number5
Pages (from-to)413-420
Number of pages8
ISSN0902-4441
DOIs
Publication statusPublished - May 2014
MoE publication typeA1 Journal article-refereed

Fields of Science

  • chronic myeloid leukemia
  • interferon
  • immune system
  • tyrosine kinase inhibitor
  • therapy discontinuation
  • NATURAL-KILLER-CELLS
  • CHRONIC MYELOGENOUS LEUKEMIA
  • CD8(+) T-CELLS
  • CML PATIENTS
  • MESYLATE DISCONTINUATION
  • INTERFERON-ALPHA
  • NK-CELLS
  • REMISSION
  • THERAPY
  • DASATINIB
  • 3121 Internal medicine

Cite this

Koskenvesa, Perttu ; Kreutzman, Anna ; Rohon, Peter ; Pihlman, Markus ; Vakkila, Emmi ; Rasanen, Anu ; Vapaatalo, Mirja ; Remes, Kari ; Lundan, Tuija ; Hjorth-Hansen, Henrik ; Vakkila, Jukka ; Simonsson, Bengt ; Mustjoki, Satu ; Porkka, Kimmo. / Imatinib and pegylated IFN-alpha 2b discontinuation in first-line chronic myeloid leukemia patients following a major molecular response. In: European Journal of Haematology. 2014 ; Vol. 92, No. 5. pp. 413-420.
@article{9eb5f0e57dae41e399d269655fa97f53,
title = "Imatinib and pegylated IFN-alpha 2b discontinuation in first-line chronic myeloid leukemia patients following a major molecular response",
keywords = "chronic myeloid leukemia, interferon, immune system, tyrosine kinase inhibitor, therapy discontinuation, NATURAL-KILLER-CELLS, CHRONIC MYELOGENOUS LEUKEMIA, CD8(+) T-CELLS, CML PATIENTS, MESYLATE DISCONTINUATION, INTERFERON-ALPHA, NK-CELLS, REMISSION, THERAPY, DASATINIB, 3121 Internal medicine",
author = "Perttu Koskenvesa and Anna Kreutzman and Peter Rohon and Markus Pihlman and Emmi Vakkila and Anu Rasanen and Mirja Vapaatalo and Kari Remes and Tuija Lundan and Henrik Hjorth-Hansen and Jukka Vakkila and Bengt Simonsson and Satu Mustjoki and Kimmo Porkka",
year = "2014",
month = "5",
doi = "10.1111/ejh.12258",
language = "English",
volume = "92",
pages = "413--420",
journal = "European Journal of Haematology",
issn = "0902-4441",
publisher = "Wiley",
number = "5",

}

Imatinib and pegylated IFN-alpha 2b discontinuation in first-line chronic myeloid leukemia patients following a major molecular response. / Koskenvesa, Perttu; Kreutzman, Anna; Rohon, Peter; Pihlman, Markus; Vakkila, Emmi; Rasanen, Anu; Vapaatalo, Mirja; Remes, Kari; Lundan, Tuija; Hjorth-Hansen, Henrik; Vakkila, Jukka; Simonsson, Bengt; Mustjoki, Satu; Porkka, Kimmo.

In: European Journal of Haematology, Vol. 92, No. 5, 05.2014, p. 413-420.

Research output: Contribution to journalArticleScientificpeer-review

TY - JOUR

T1 - Imatinib and pegylated IFN-alpha 2b discontinuation in first-line chronic myeloid leukemia patients following a major molecular response

AU - Koskenvesa, Perttu

AU - Kreutzman, Anna

AU - Rohon, Peter

AU - Pihlman, Markus

AU - Vakkila, Emmi

AU - Rasanen, Anu

AU - Vapaatalo, Mirja

AU - Remes, Kari

AU - Lundan, Tuija

AU - Hjorth-Hansen, Henrik

AU - Vakkila, Jukka

AU - Simonsson, Bengt

AU - Mustjoki, Satu

AU - Porkka, Kimmo

PY - 2014/5

Y1 - 2014/5

KW - chronic myeloid leukemia

KW - interferon

KW - immune system

KW - tyrosine kinase inhibitor

KW - therapy discontinuation

KW - NATURAL-KILLER-CELLS

KW - CHRONIC MYELOGENOUS LEUKEMIA

KW - CD8(+) T-CELLS

KW - CML PATIENTS

KW - MESYLATE DISCONTINUATION

KW - INTERFERON-ALPHA

KW - NK-CELLS

KW - REMISSION

KW - THERAPY

KW - DASATINIB

KW - 3121 Internal medicine

U2 - 10.1111/ejh.12258

DO - 10.1111/ejh.12258

M3 - Article

VL - 92

SP - 413

EP - 420

JO - European Journal of Haematology

JF - European Journal of Haematology

SN - 0902-4441

IS - 5

ER -